Blood & Cancer artwork

Hem-Onc News: No benefit from postop radiotherapy in NSCLC; sotorasib is a 'triumph of drug discovery'; and choosing TKI for ALL

Blood & Cancer

English - September 29, 2020 08:00 - 13 minutes - 18.7 MB - ★★★★★ - 31 ratings
Medicine Health & Fitness Science Life Sciences oncologists radiotherapy cancer chemotherapy doctors healthcare hematologists hematology immunotherapy marrow Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Studying cancer patients with COVID-19: Dr. Brian Rini describes the NCCAPS and CCC19 studies and reviews the latest findings

Next Episode: ESMO 2020: Late-breaking and practice-changing studies on COVID-19 and breast, lung, gastrointestinal, and other cancers

Hematology-Oncology News:

No benefit with postoperative radiotherapy in stage IIIA2 NSCLC (https://bit.ly/3i1196r)
ESMO meeting abstract: https://bit.ly/2RZwig4 First-in-class ADC ups survival in mTNBC (https://bit.ly/2GaoVQ2)
ASCENT study: https://bit.ly/2Ey54df Sotorasib is a 'triumph of drug discovery' in cancer (https://bit.ly/2FQwpIt)
CodeBreak100 trial: https://bit.ly/342dJNV TKI choice key for fit/unfit patients with Ph+ALL (https://bit.ly/3kLdmOs)

Email Blood & Cancer at [email protected]